Opportunity Information: Apply for PAR 13 087
Apply for PAR 13 087
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on May 9, 2014 and posted on Jan 11, 2013.
- Applicants must submit their applications by May 9, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cooperative Drug Discovery/Development Groups (NCDDG) program is an NIH funding opportunity that supports team-based, multidisciplinary efforts to discover and develop new pharmacological treatments and research tools for mental disorders and for drug or alcohol addiction. It is designed to bring together complementary expertise, often spanning basic science, medicinal chemistry, pharmacology, toxicology, translational science, and early clinical testing, so that promising ideas can move faster from target identification and compound discovery into practical therapeutic candidates. A central theme of the program is collaboration, with a strong preference for partnerships that effectively combine academic innovation with industry-style development capabilities.
The scientific goals of the program focus on accelerating innovative drug discovery and advancing candidate agents that are rationally designed or mechanistically informed. Projects are expected to contribute to one or more of the following: identifying and optimizing novel therapeutic compounds; developing pharmacologic tools such as new ligands that can probe biological mechanisms or validate drug targets; creating and validating experimental models that help predict how new therapeutics might perform; and supporting early phase human studies when appropriate. In practical terms, the program aims to shorten the timeline between discovery and real-world testing by encouraging work that bridges preclinical development and proof-of-concept evaluation, including safety and preliminary efficacy assessments in humans for the most promising candidates.
A distinctive feature is the emphasis on agents that are either new candidates or new uses for agents that are already IND-ready, meaning they are sufficiently developed for Investigational New Drug-related activities and can potentially move into early clinical evaluation more rapidly. This includes exploring new indications for compounds that have a development pathway already in place, as long as the scientific rationale supports their potential benefit for mental health conditions or alcohol addiction. Alongside therapeutic development, the program also values the creation of high-quality chemical probes and ligands that can serve as enabling tools for both basic and clinical research, helping researchers better characterize existing targets or validate new ones that could lead to future treatments.
This opportunity is offered as a cooperative agreement (UM1), which typically indicates substantial scientific or programmatic involvement by the NIH during the course of the award. In general, cooperative agreements are structured to support complex, milestone-driven projects where close coordination with the funding institute can help keep development efforts aligned with translational goals, facilitate problem-solving, and ensure that key go/no-go decisions are made using clear evidence. The participating NIH institutes include the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), reflecting the program’s coverage across mental illness and substance use-related disorders.
Eligibility is broad across the U.S. research ecosystem. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits), for-profit organizations (including small businesses and other for-profits), and several institution types specifically noted as eligible, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISISs. Foreign institutions and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components as defined by NIH policy are allowed, which can enable certain international collaborations when they are part of an otherwise eligible U.S.-based application.
Administratively, the program is listed under Funding Opportunity Number PAR 13-087 and is categorized as a discretionary opportunity using the cooperative agreement funding instrument. It falls under health and education-related activity categories and is associated with CFDA numbers 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), and 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement. The announcement was originally posted in January 2013 and has since been archived, with key dates indicating an original closing date in October 2015 and an archive date in November 2015. The full announcement and official details were provided through the NIH grants policy and guide materials referenced in the source link.
Overall, this program was built for ambitious, coordinated drug discovery and early development efforts where the end goal is not just publishing mechanistic findings, but delivering credible therapeutic candidates or enabling pharmacologic tools for mental disorders and addiction. The strongest projects under this model are typically those with clear target rationale, a practical development plan, well-justified models and endpoints, and a credible path to early clinical testing or IND-enabling readiness, supported by a partnership structure that can execute across the entire discovery-to-proof-of-concept pipeline.
Frequently Asked Questions (FAQs)
What is the National Cooperative Drug Discovery/Development Groups (NCDDG) program?
The NCDDG program is an NIH funding opportunity that supports team-based, multidisciplinary projects to discover and develop new pharmacological treatments and research tools for mental disorders and for drug or alcohol addiction.
What is the main purpose of this funding opportunity?
The program is designed to speed up the path from scientific discovery to practical testing by combining complementary expertise (for example, basic science through early clinical testing) so promising targets and compounds can move faster toward credible therapeutic candidates or enabling pharmacologic tools.
What kinds of projects does the program aim to support?
Projects are expected to advance innovative drug discovery and the development of candidate agents that are rationally designed or mechanistically informed, with a strong emphasis on collaboration and coordinated development efforts.
What scientific areas or disciplines are typically involved?
The opportunity highlights multidisciplinary teams that may include expertise in basic science, medicinal chemistry, pharmacology, toxicology, translational science, and early clinical testing.
Is collaboration a requirement or preference?
Collaboration is a central theme of the program, with a strong preference for partnerships that combine academic innovation with industry-style development capabilities.
What specific activities or outcomes are projects expected to contribute to?
Projects are expected to contribute to one or more of the following: identifying and optimizing novel therapeutic compounds; developing pharmacologic tools (such as new ligands) to probe mechanisms or validate targets; creating and validating experimental models that help predict performance of new therapeutics; and supporting early phase human studies when appropriate.
Does the program support early clinical testing in humans?
Yes. The program may support early phase human studies when appropriate, including safety and preliminary efficacy (proof-of-concept) assessments for the most promising candidates.
What does the program mean by shortening the timeline from discovery to testing?
It encourages work that bridges preclinical development and proof-of-concept evaluation, helping move projects beyond mechanistic findings toward real-world testing steps, including go/no-go decisions supported by evidence.
What types of agents are especially emphasized?
A distinctive feature is an emphasis on agents that are either new candidates or new uses for agents that are already IND-ready (sufficiently developed for Investigational New Drug-related activities), which may allow faster movement into early clinical evaluation.
Are new indications for existing compounds allowed?
Yes. The program includes exploring new indications for compounds that already have a development pathway in place, as long as there is a strong scientific rationale for potential benefit in mental health conditions or alcohol addiction.
Does the program fund research tools as well as therapeutics?
Yes. In addition to therapeutic development, the program values high-quality chemical probes and ligands that can enable both basic and clinical research by characterizing targets or validating new ones.
What is the funding mechanism used for this opportunity?
This opportunity is offered as a cooperative agreement (UM1), which generally indicates substantial scientific or programmatic involvement by NIH during the award.
What does a cooperative agreement (UM1) imply for how the project is managed?
Cooperative agreements are typically used for complex, milestone-driven projects where close coordination with NIH helps keep development aligned with translational goals, supports problem-solving, and uses clear evidence for key go/no-go decisions.
Which NIH institutes participate in this program?
The participating NIH institutes include the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
What disease or condition areas does the program cover?
The program covers mental disorders and substance use-related disorders, including drug or alcohol addiction, reflecting the involvement of NIMH, NIDA, and NIAAA.
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), and for-profit organizations (including small businesses and other for-profits).
Are minority-serving institutions specifically eligible?
Yes. The eligible institution types specifically noted include HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISISs.
Are foreign institutions eligible to apply as the main applicant?
No. Foreign institutions and non-U.S. components of U.S. organizations are not eligible to apply.
Are any international collaborations allowed?
Yes. While foreign institutions cannot apply as the main applicant, foreign components (as defined by NIH policy) are allowed, which can support certain international collaborations as part of an otherwise eligible U.S.-based application.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the Funding Opportunity Number for this program?
The Funding Opportunity Number is PAR 13-087.
What activity categories and CFDA numbers are associated with this opportunity?
The opportunity is associated with health and education-related activity categories and CFDA numbers 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), and 93.279 (Drug Abuse and Addiction Research Programs).
Is this opportunity still open?
No. The announcement was originally posted in January 2013, had an original closing date in October 2015, and was archived in November 2015.
What kinds of project characteristics are described as strongest under this model?
The description emphasizes projects with a clear target rationale, a practical development plan, well-justified models and endpoints, a credible path to early clinical testing or IND-enabling readiness, and a partnership structure capable of executing across the discovery-to-proof-of-concept pipeline.
Browse more opportunities from the same category: Education Health
Next opportunity: Building Disaster Resilient Communities in Southern Africa
Previous opportunity: National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 087
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 087) also looked into and applied for these:
| Funding Opportunity |
|---|
| Planning for a National Center for Particle Beam Radiation Therapy Research (P20) Apply for PAR 13 096 Funding Number: PAR 13 096 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI Experimental Therapeutics Clinical Trials Network with Phase 1 Emphasis (ET CTN) (UM1) Apply for RFA CA 13 006 Funding Number: RFA CA 13 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $850,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R01) Apply for RFA NR 13 002 Funding Number: RFA NR 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R21) Apply for RFA NR 13 003 Funding Number: RFA NR 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Collaborative Human Tissue Network (CHTN) (UM1) Apply for RFA CA 13 007 Funding Number: RFA CA 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,200,000 |
| Research on Marijuana Legalization in the US (Admin Supp) Apply for PA 13 138 Funding Number: PA 13 138 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Lasker Clinical Research Scholars Program (Si2) Apply for RFA OD 13 004 Funding Number: RFA OD 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Multicenter AIDS Cohort Study Center for the Coordination, Analysis, and Management of the MACS (CAMACS)(UM1) Apply for RFA AI 13 010 Funding Number: RFA AI 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,400,000 |
| Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01) Apply for RFA AI 13 011 Funding Number: RFA AI 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $4,200,000 |
| Limited Competition Scholars Training for the Advancement of Research (STAR) Revision to NINR T32 Training Grants (T32) Apply for RFA NR 13 010 Funding Number: RFA NR 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Apply for PAR 13 146 Funding Number: PAR 13 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 14 003 Funding Number: RFA DA 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 13 157 Funding Number: PA 13 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) Apply for PAR 13 158 Funding Number: PAR 13 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 13 163 Funding Number: PAR 13 163 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01) Apply for PA 13 165 Funding Number: PA 13 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15) Apply for PA 13 166 Funding Number: PA 13 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R21) Apply for PA 13 167 Funding Number: PA 13 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 13 159 Funding Number: PAR 13 159 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 13 169 Funding Number: PAR 13 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 087", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.